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Abstract
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed in advanced
stage and therefore requires aggressive, multimodal treatment. Elderly patients are
often excluded from standard therapy regimens purely based on age. This clinical
review aims to collect all published data in the literature on treatment modality
selection in elderly patients and on age-related adverse events following treatment
of HNSCC. We performed a literature search for articles on the treatment of
HNSCC in elderly patients. Most of the articles were retrospective studies with the
consequent limitations. It can be concluded that age is not an absolute contraindica-
tion for intensive treatment and comorbidity is an important predictor of outcome,
but not the only one. Despite the existence of multiple tools for pretreatment
evaluation, there are not consistent data on their use.
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1 | INTRODUCTION
Despite the increase of a subpopulation of relatively younger
head and neck squamous cell cancer (HNSCC) patients with
human papillomavirus (HPV) related oropharyngeal cancer
patients, HNSCC remains primarily a cancer of an older popu-
lation. According to the Surveillance, Epidemiology, and End
Results (SEER) database, approximately 64% of all patients
diagnosed with HNSCC in the United States between 1975
and 2014 were ≥65 years.1 It has been estimated that 24% of
newly diagnosed HNSCC patients are older than 70 years2,3
and the larynx, oropharynx, and oral cavity are the three
tumor sites most common affected.4 The definition of “elderly”
is not uniform and different cut points are used for this pur-
pose. However, the National Institute on Aging suggest catego-
ries of “young old” (65-74 years), “older old” (75-85 years),
and “oldest old” (>85 years).5 The majority of patients with
HNSCC present with advanced stage disease which usually
requires extensive combined treatment, that is, surgery and
postoperative radiotherapy (RT) with or without CT or primary
RT with or without systemic therapy (CT or cetuximab) with
salvage surgery, when needed and possible.6 These intensive
multimodality treatments harbor a high risk of associated acute
and long-term toxicity, which in many cases is demonstrated
by poor adherence to treatments, inferior quality of life (QoL),
treatment-induced death, and limited life expectancy.7 In
elderly patients, medical comorbidities are common. As such,
these patients are considered poor candidates for intensive mul-
timodal therapy and frequently they receive less effective but
better tolerated treatments regimens, often with a poorer
response.8 The selection of patients for either standard or non-
standard therapy is not clearly defined, and a comprehensive
geriatric evaluation is rarely conducted. Fear of adverse events
in these elderly patients often results in different treatment of
elderly as compared to younger patients. An adverse event can
be defined as any unfavorable and unintended sign, symptom,
or disease temporally associated with the use of a medical
treatment or procedure that may or may not be considered
related to the medical treatment or procedure,9 thus, subjective
factors frequently influence the decision on treatment.10 In the
last years, the concept of frailty has been developed. The term
frailty refers to a state of decreased physiological reserves, aris-
ing from cumulative deficits in several physiological systems
and resulting in a diminished resistance to stressors.11,12
Research has been conducted to find screening methods to
identify fit older patients who are able to receive standard can-
cer treatment, and vulnerable patients who should subsequently
receive a geriatric assessment to guide tailoring of their treat-
ment.13 Moreover, elderly patients are frequently not included
in prospective clinical trials. These trials often accrue younger
and healthier patients, as described by Siddiqui and Gwede.14
They found that the median age of the patients enrolled was
between 53 and 62 years old and most studies lack data on
comorbidities. Therefore, recommendations derived from these
trials and guidelines based on their results are not directly
applicable to older patients. Another factor is the reluctance of
physicians to offer the best available therapy, based on the
belief that older people are not fit to receive complex surgical
procedures or intense chemoradiotherapy (CRT).15
The purpose of this article is to review the currently
available literature with focus on (1) the importance of age
in the treatment selection for HNSCC, (2) if these patients
legitimately receive nonstandard treatment regimens, (3) if
elderly HNSCC patients more often face treatment-related
adverse events and worse survival in contrast to their youn-
ger counterparts and finally, and (4) if in the published arti-
cles any screening method is used to assess if older patients
are candidates for standard treatment.
For this purpose, the Preferred Reporting Items for Sys-
tematic Review and Meta-Analyses were used to conduct a
systematic review of the current literature.16 The search strat-
egy aimed to include all articles concerning the treatment of
HNSCC in elderly patients. A PubMed internet search updated
to July 24, 2018 was performed for English language publica-
tions between the years 1980 and 2018 using the following
search criteria in the title or abstract: “head and neck cancer,”
coupled with “older,” “elderly” or “age,” and “radiotherapy,”
“chemotherapy,” “systemic therapy,” “targeted therapy,” “sur-
gery,” and “adverse event.” The search results were reviewed
for potentially eligible studies. When there was reference in
the abstract that the study includes patients over 65 years old,
the full text article was searched; all review articles were also
checked in full. References from any full text articles were
cross-checked to ensure inclusion of all relevant publications
in this review (Figure 1). Studies were selected if they met the
following inclusion criteria: (1) patients treated for HNSCC,
(2) age of the patients ≥65 years, (3) type of treatment that the
patients received, (4) data about the primary site of the tumor,
and (5) if the study included also younger patients, data should
be analyzed by age group (eg, >65 years, <65 years). Studies
involving patients of all ages, without age differentiation, were
excluded.
According to our search criteria, 2543 papers were initially
identified. After sorting and removal of duplicates, 82 papers
that fully fit our inclusion criteria were retrieved, reviewed in
detail, and summarized in Tables 1–4 according to the modality
of treatment used: RT, systemic therapy (CT or targeted ther-
apy), surgery, or multimodal therapy.4,15,17–96





Most studies find no age-specific differences in the efficacy of
radiation therapy,4,17 and note comparable survival outcome.
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However, the data on treatment-related toxicity differ among
studies. For instance, Pignon et al4 found more severe but not
more frequent acute toxicities in aged patients, and contradic-
tory to this, Schofield et al21 found no differences. The study
by Allal et al20 indicates the lack of compliance of elderly
patients to accelerated radiotherapy.
2.1.2 | Specific RT techniques
Specific RT techniques and protocols, such as intensity modu-
lated radiotherapy (IMRT),22,25 intensity modulated radio-
therapy/image guided radiotherapy simultaneous integrated
boost (IMRT/IGRT SIB),23 and hypofractionation,24 seem to
be feasible and well-tolerated in elderly. Based on the pub-
lished literature, age itself seems not to be a limiting factor in
curative radical RT, even in the octogenarian18 and nonage-
narians.19 However, data on efficacy, toxicity, and compliance
in the very old patients is based on small study populations.
In addition, the proportion of older patients in these trials is
lower compared to the fraction they represent among all
HNSCC patients, which implies a significant selection
bias. Despite only apparently “fit elderly” (individuals, over
65 years of age, living independently at home or in sheltered
accommodation97) patients are recruited to curative-intent
radiotherapy programs, the meta-analysis of prospective ran-
domized trials comparing conventional and altered fraction-
ated radiotherapy showed a decreasing effect (worse overall
survival, but not the disease-specific survival) of intensified
radiotherapy regimens with increasing effect.98,99 Increase in
non-cancer-related deaths and lower compliance and tolerance
were recognized as possible factors for this observation.100,101
However, the difference between chronological and biological
age of the patients, the parameter that was not addressed in
the meta-analysis, could also play a role.10
Based on the presented data, it appears that altered frac-
tionated radiotherapy has a decreased benefit in older
patients and in patients with poor performance status. It
could be due to an excess of non-cancer-related deaths but
also by lower compliance and tolerance in older patients;
although late toxicity and outcomes are not different, asking
for careful selection of elderly patients for curative intent
radiotherapy regimens.
2.2 | Chemotherapy and other systemic therapy
2.2.1 | Chemoradiation, bioradiation
Adding CT to radiation therapy for the treatment of HNSCC
in elderly patients is often discarded from treatment proto-
cols, based on a meta-analysis of Pignon et al in 2009
(MACH-HN).102 This study concluded that adding CT to
conventional RT has no beneficial effect in patients over 70.
There are several points of criticisms on this conclusion; one
of these is the fact that non-cancer-related deaths were more
common in the elderly and significantly altered the analysis.
A similar observation was made by Machtay et al,57 who
analyzed three RTOG chemoradiation trials (12% of patients
were over 70) for the factors influencing the occurrence of
severe (grade 3-4) late toxicities with potential detrimental
effect to survival: the risk of their development was signifi-
cantly increased with higher age (hazard ration 1.05 per
year). Another limitation of the MACH-HN study is the
small number (356 patients) of elderly patients who received
CRT, compared to the whole study population, which was
over 17 000 patients.
A more recent addition to systemic HNSCC treatment is
cetuximab, a monoclonal antibody directed against the epider-
mal growth factor receptor, approved in 2006 for concurrent
use with radiation in locally or regionally advanced disease81
was demonstrated not to increase common acute radiation-
associated toxicity or a decline of patient's QoL.103 However,
in older patients (≥65 years), no overall survival benefit was
reported when used in combination with RT.104
2.2.2 | Systemic therapy for recurrent/metastatic
(RM) disease
In the EXTREME trial, which stated the superiority of
cetuximab added to platinum and 5-fluorouracil (PF) in com-
parison to PF alone in first-line setting for RM HNSCC, only
18% of the patients were 65 years and older.28 The highest
benefit in survival for the three-drug regimen was observed
in patients with <65 years (HR 0.74; 0.59-0.94), whereas it
was not significant in older patients (HR 1.07; 0.65-1.77).
Gebbia et al26 showed that fit elderly can receive CT without
major age-related toxicity, underlining the importance of
screening. The outcome of a phase III open-label trial was
consistent with this study, and the results showed that
advanced age does not adversely affect toxicity and onco-
logic outcome in patients treated in a second-line setting
with afatinib or methotrexate.29 In contrast to these two stud-
ies, Argiris et al27 found significantly higher toxicity rates
and also higher CT-related deaths in elderly; however,
global survival data of elderly were comparable to the youn-
ger patients. These data are based on the analysis of two
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FIGURE 1 Flowchart showing the process of the study selection for the
systematic review





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2414 COCA-PELAZ ET AL.
phase III Eastern Cooperative Oncology Group (ECOG) stud-
ies on palliative cisplatin-based studies with only 13% of the
patients from ≥70 age group. Observed differences are very
likely due to the differences in eligibility for receiving CT
across different age groups, indicating a need for more effective
strategies for decreasing toxicities in elderly patients.
Nakano et al30 compared the efficacy of two cetuximab-
containing regimens (weekly paclitaxel and cetuximab vs
PF, platinum, and cetuximab). They found that male, older
age (≥70 years), good performance status, no history of plat-
inum chemotherapy, and the presence of a tracheostomy
were favorable factors within the cohort treated with weekly
paclitaxel and cetuximab.
Obviously, age-related changes in physiology of differ-
ent organs alter pharmacokinetics and pharmacodynamics of
systemic drugs, which increase susceptibility of normal tis-
sues to toxicity. Changes in toxicity profile observed in older
patients reduce tolerability to systemic therapies and require
more effective supportive care measures; in this regard, the
importance of tools for prediction of the risk of toxicity and
the probability of response before administering systemic
therapies should be underlined.27
2.3 | Surgery
The literature on the effect of age on treatment-related
adverse events in patients undergoing major head and neck
surgery is very consistent. However, all available literature
data are based on retrospective studies, which very likely
introduce selection bias in the inclusion of patients in these
studies. Surgical candidates are usually thoroughly screened
before major oncological head and neck surgery and only fit
elderly patients are selected for these complex procedures.
Usually, patients who are excluded are not analyzed, and
their outcome is unknown. Therefore, these studies have to
be carefully interpreted.
Roughly, two types of studies can be identified in this
topic; studies comparing young vs elderly and studies includ-
ing only aged patients. All studies that compare complication
rates31–35,37,40–43,105 conclude that complication rate is compa-
rable in elderly and young patients, except the study of Mor-
gan et al.31 Despite the fact that the latter study finds slightly
more frequent complications in elderly patients (32% vs
21%), the authors concluded that age alone should not be a
factor to exclude patients from extensive surgery.31 Retro-
spective studies with cohorts of elderly patients that lack a
control group34,36,38,39,44,45 draw the same conclusions; surgi-
cal treatment can be safely performed in elderly HNSCC
patients and selection should be based on medical assessment,
and not on age. Although most of the studies focused on com-
plication rates, a small subset does report survival data.35
Interestingly, Clayman et al35 found lower local control and
disease-specific survival in octogenarians when compared
with group of similar patients aged up to 65 years.
2.4 | Multimodality treatment
The literature on age-specific treatment outcome after
multimodality treatment is not very consistent. Several
studies confirm no age-related differences after multi-
modal treatment of HNSCC in terms of treatment-
related adverse events.46,47,49,60,62–64,68,77,106 In contrast,
other studies identified more adverse events in the
elderly.54,57,58,66,67,69,72,75,78,79,87 As all of these studies
are retrospective, the selection bias may have had an effect
on the outcome. This problem is highlighted in the study
of Hirano and Mori.48 These authors found significant dif-
ferences between young and old patients regarding the
choice of the modalities of curative treatment, due to sig-
nificantly more common concomitant comorbidities in
elderly. In the study of Derks et al,53 the proportion of
patients aged 45-60, 70-79, and ≥80 year that received
standard treatment was 89%, 75%, and 35%, respectively;
whereas no treatment was given to 4%, 13%, and 18% of
the patients from respective groups.
Comparing survival between cohorts of different age
categories is difficult due to expected differences in life
expectancy. Some studies confirm poorer survival in the
elderly after multimodality treatment,50,51,62,69,93,94 others
report comparable survival in the elderly to the younger
cohorts.46,47,66,75,87 Concerning the rate of treatment-
related death, Sarini et al49 did not find any age-specific
differences.
In the past, elderly patients were clearly underrepresented
in non-age-related clinical trials. However, the number of
studies on the eligibility of elderly for intensive multimodal
treatment is exponentially increasing. It seems that the old
dogma, that elderly patients should be excluded from standard
treatment protocols, purely based on their chronological age
does not stand any longer. This is also reflected in the out-
come of a recent study on the SEER database, confirming the
increased use of chemoradiation and particularly cetuximab,
in older patients over the past decades.81
3 | FACTORS INFLUENCING ADVERSE
EVENTS
3.1 | Comorbidity, advanced stage, use of CT
One of the key factors in the decision on treatment of a
patient with HNSCC is comorbidity. Comorbidity is defined
as one or more unrelated diseases present at the time of can-
cer diagnosis.10 In elderly patients, comorbidity is more fre-
quent, and these patients sometimes receive nonstandard
treatments due to the fear of complications, that intensive
standard treatments entail. For this reason, these patients are
often offered nonsurgical treatments or surgical treatment
without postoperative RT.49,53,107 Peters et al63 reported on a
cohort of elderly patients with oropharyngeal cancer, and no
difference in posttreatment complications between young























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2424 COCA-PELAZ ET AL.
and old patients was found, despite the higher incidence of
comorbidity in elderly patients. T-classification was the only
factor associated with the frequency of complications in
multivariate analysis. This observation was confirmed by
Zabrodsky et al.38 They reported that surgical and medical
complications were influenced by advanced comorbidity,
long operative times, and advanced stage at diagnosis.
Sanabria et al39 observed that advanced stage was associated
with postoperative complications as well, and identified
additional factors that contributed: male, bilateral neck
dissection, and presence of two or more comorbidities.
Advanced stage at diagnosis is often considered a predictor
for postoperative complications.41,42,63,64 One of the factors
studied as influential in the incidence of adverse effects in
the elderly is the addition of CT to RT. For example, in the
study by O'Neill et al,78 a higher rate of hospitalization and
acute toxicity with emergency room visit was found in
patients receiving CRT vs RT treatment. The group also
reported a higher rate of acute treatment-related toxicity,
feeding tube placement, and long-term feeding tube depen-
dence among these older patients treated with combined
modality therapy. Similar results were reported by Strom
et al.108 This report evaluated patients by age, rather than by
treatment modality, and found an increased rate of hospital
admission and a late percutaneous endoscopic gastrostomy
dependence among older patients treated with CRT. Michal
et al66 confirmed these observations as well.
3.2 | Other prognosticators
Other factors possibly related to adverse events during treat-
ment of the elderly patients with HNSCC have also been stud-
ied. Besides comparing young and elderly patients, a
significant proportion of these studies attempted to identify
predictors of outcome other than age. Comorbidity, perfor-
mance status, frailty, and advanced tumor stage all seem to cor-
relate with clinical outcome.39,56,59,63,64,67,80,83,85–87,93,95,96,106
Beside the known general prognosticators for surgical compli-
cations, like advanced stage and previous RT, the duration of
the surgery plays a role. In fact, prolonged surgery time was
found to be a significant independent predictor for surgical
complication in these studies.38,41,44,105 However, the ability of
older patients to cope with the proposed treatment goes beyond
the comorbidity status and includes other aspect of patient
functioning with assessment of the nutritional status, polyphar-
macy, cognitive function, socioeconomic issues, and geriatric
syndromes.109
3.3 | Coordination of care
Apart from these observations, the majority of the authors
agree that older patients can receive the same treatment
as younger ones, with comparable or higher complication
rates. A higher chance on complications as such does not
imply not to give treatment, but calls for better planning,
better preoperative evaluation, and optimal multidisciplinary
team coordination, including supportive care, to minimize
treatment-related complications, maximize postoperative or
post-(chemo)radiotherapy support and decrease the impact
on survival and QoL. Introduction of enhanced recovery
after surgery (ERAS) strategy in other oncologic procedures
can be considered a demonstration of this philosophy. The
ERAS programs have been applied successfully in the last
two decades to offer a faster recovery, reducing hospital
stay, and thus fostering early return to daily activities after
hospital discharge.110
Other factors that are important for optimal recovery and
QoL after treatment are social and family support, care-
givers' availability and resilience, and financial support.
Studies have demonstrated that living alone,111 lack of psy-
chological support,112 and lack of social support113 are prog-
nostic factors of QOL decline after treatment.
4 | THE SELECTION OF PATIENTS FOR
THERAPY
4.1 | Comprehensive geriatric assessment (CGA) and
frailty tests
Attempting to predict adverse events of a given treatment in
elderly patients is much more difficult than in young
patients. It is preferable in elderly patients to evaluate the
potential impacts of treatment on the QoL, survival, and the
potential for adverse events. With this knowledge, older
patients who may benefit from intensified treatment can be
better selected for the most appropriate treatment. One of the
available options for this assessment is the CGA which is
defined as a “multidimensional interdisciplinary diagnostic
process focused on determining a frail older person's medi-
cal, psychological and functional capability in order to
develop a coordinated and integrated plan for treatment and
long term follow up.”114 CGA is therefore both a diagnostic
and therapeutic tool. It seeks to ensure that problems are
identified, quantified, and managed appropriately. A CGA is
now considered as the gold standard by some authors to
assess whether individual patients can undergo a certain
(radical) treatment, or not, based on their vulnerability. How-
ever, as suggested by Neve et al,86 to avoid overuse of this
complex time-consuming assessment instrument, the most
feasible option is to use a “screening” tool first, in order to
identify patients who are truly “vulnerable” and therefore
require further examination by a CGA (two-step approach).
Other patients recognized in the screening phase as “fit” do
not require further examination. In order to identify frail
patients, several tools are available, like the Geriatric 8 (G8),
the Flemish version of the Triage Risk Screening Tool
(fTRST), the Groningen Frailty Indicator (GFI), the Vulnera-
ble Elders Survey-13 (VES-13), and an abbreviated CGA.115
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4.2 | Predictive value of CGA items and frailty tests
As described by Hamaker et al11 in a recent systematic review,
the predictive value of these frailty tests can be questioned as
some tests are highly sensitive for frailty but their specificity
and negative predictive value are rather poor. In HNSCC, the
G8 appears to be the diagnostic screening tool with a greater
ability to select vulnerable patients, who should need a full
CGA.116 In our review, only 2 studies use some kind of geriat-
ric, QoL, or functional assessments among the RT trials,24,25
2 studies of the trial on systemic therapy,26,29 4 in surgical
studies,38,41,42,44 and 17 in papers on results of multimodal
treatment.15,53,55,59,63,64,67,80,83,85–87,93,95,96,106,117 Most of them
did not use a specific geriatric tool. As it is known that the
selection of a substandard treatment for an elderly patient
decreases overall and cancer-specific survival, this decision
must be based on the results of the available screening tools
and eventual CGA, not simply on chronological age.
5 | CONCLUSIONS AND
RECOMMENDATIONS
This is the first comprehensive review which systematically
assesses age-related adverse events and treatment selection
in elderly patients with HNSCC and associated survival out-
comes. Most of the studies agree that chronological age itself
should not to be a reason to exclude patients from standard
therapy. However, these data are mostly based on retrospec-
tive studies, which might introduce selection bias. Further-
more, the quality of the studies is diverse, and some data are
controversial. When selecting treatment modalities, biologi-
cal age is clearly more important than chronological age.
However, there is no gold standard to assess it. Comorbidity
and performance status of the patients are frequently ana-
lyzed and are certainly important factors, but as such seem
to be insufficient to predict treatment outcome. In fact, toler-
ance to treatment is multifactorial and also depends on psy-
chological status and various socioeconomic issues, in
addition to medical condition and the level of functioning.
Pretreatment assessment remains a crucial issue in treatment
selection. However, choosing the proper therapy remains
challenging. This process is even more complex, as patients'
preferences also need to be considered in the context of the
shared decision making and elderly are known to have other
priorities than their younger counterparts. Using frailty
screening instruments, only selected candidate patients may
be directed to more complex CGA evaluation (two-step
approach). Other promising screening tools need further
investigation of their impact in guiding the treatment deci-
sion making and in predicting toxicities, in the framework of
HNSCC prospective trials. Large scale, prospective, multi-
center studies are also needed to explore the possibility of
including more elderly HNSCC patients in guideline-based
(intensive) treatment protocols, and to select appropriate de-
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